Boulevard Bio emerged from stealth on Wednesday August 12, 2026 with $65 million in founding financing from Deerfield Management, naming Georg Schett (one of the pioneers of immune reset in autoimmune disease) as co-founder. The company disclosed a precision-immunology pipeline of three drug candidates anchored by BLVD101, an internally discovered dual BAFF/APRIL-targeting bispecific antibody. Mechanism: BLVD101 is designed to inhibit BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), two cytokines that promote the proliferation, survival, and maturation of B cells that drive autoimmune disorders. By blocking both cytokines simultaneously, BLVD101 aims to limit the abnormal B cell activity that attacks healthy tissue in autoimmune diseases. Early Phase 1 healthy volunteer data supports a 12-week (quarterly) subcutaneous dosing interval for BLVD101 in IgA nephropathy (IgAN), a positive tolerability and pharmacokinetic profile that would compare favorably against monthly-dosing biologics in adjacent indications. The launch extends the IgAN indication activity that Trutakna and Fabhalta opened up earlier in 2026 with their FDA approvals ten days apart in the same indication category, though those two drugs target the complement pathway (factor B, C5) rather than the B-cell BAFF/APRIL axis that BLVD101 addresses.
Vera Therapeutics (NASDAQ: VERA) confirmed commercial-launch parameters for TRUTAKNA (atacicept-vymj) following the July 7, 2026 FDA accelerated approval for adults with primary IgA nephropathy at risk of rapid disease progression. List price: $425,000 per year for the recombinant peptide-and-Fc fusion protein (TACI extracellular domain fused to human IgG1 Fc). Sales force: 82 representatives deployed at launch. Distribution: in-channel pharmacy availability within three to four weeks of approval, with insurance coverage under specialty-pharmacy medical benefit pathways given the subcutaneous injection administration. The July 7 accelerated approval was based on the Phase 3 ORIGIN study 36-week urine protein-to-creatinine ratio (UPCR) endpoint (45.7% reduction versus 6.8% for standard of care). Continued FDA approval may be contingent on verification of clinical benefit in the ongoing ORIGIN 3 confirmatory trial, which continues in a placebo-controlled blinded manner to evaluate change in kidney function as measured by estimated glomerular filtration rate (eGFR); results are anticipated in Q3 2026. If the ORIGIN 3 eGFR data hit, TRUTAKNA converts to traditional approval on the harder outcome endpoint.
Vertex Pharmaceuticals' (NASDAQ: VRTX) povetacicept, a BAFF/APRIL-blocking fusion protein for primary IgA nephropathy, has US FDA acceptance of its Biologics License Application with a PDUFA target action date of November 30, 2026. Povetacicept works through the same mechanism as Vera Therapeutics' TRUTAKNA (atacicept-vymj), targeting the BAFF and APRIL cytokines that drive plasma-cell antibody production. Phase 3 topline data reported in March 2026 showed a 49.8% reduction in urine protein-creatinine ratio (UPCR) at 36 weeks in povetacicept-treated patients versus placebo (versus 45.7% for TRUTAKNA in the ORIGIN Phase 3). BioSpace analysis published this weekend characterizes the Vertex program as derisked following the Vera TRUTAKNA approval on July 7 and the Novartis Fabhalta traditional approval on July 17 — both marketing campaigns will build IgAN awareness and educate nephrologists on the treatment landscape before povetacicept reaches market, and both approvals validate the FDA's willingness to green-light novel IgAN mechanisms on accelerated pathways. Povetacicept, if approved, would become the first commercialized therapy in Vertex's emerging nephrology franchise.
The FDA granted accelerated approval Tuesday July 7, 2026 to Trutakna (atacicept-vymj) for adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression, in combination with standard of care. Vera Therapeutics developed the drug as a recombinant fusion protein that combines the extracellular domain of the transmembrane activator and CAML interactor (TACI) receptor with the Fc portion of human IgG1, binding both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) to reduce autoantibody-driven kidney damage. The registrational Phase 3 ORIGIN trial data supporting approval: at 36 weeks, Trutakna plus standard of care produced a 45.7% reduction in urine protein-to-creatinine ratio versus a 6.8% reduction for standard of care alone. IgA nephropathy affects approximately 130,000 to 150,000 Americans and is the most common primary glomerular disease worldwide; approximately 40% of patients progress to end-stage renal disease within 20 years without adequate treatment. Trutakna is a fusion protein rather than a peptide but sits in adjacent therapeutic territory relevant to the site's peptide-and-biologic coverage. Vera Therapeutics (NASDAQ: VERA) is expected to launch the product in Q3 2026. Continued approval may be contingent on verification of clinical benefit in confirmatory Phase 3 studies.